1
|
Elgin U, Sen E, Ozdemir K, Ozdal P, Berker N. The outcome of initial mitomycin C-augmented trabeculectomy with subconjunctival bevacizumab in the management of secondary glaucoma associated with Fuchs heterochromic iridocyclitis. Int Ophthalmol 2019; 40:795-802. [PMID: 31792855 DOI: 10.1007/s10792-019-01240-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Accepted: 11/19/2019] [Indexed: 10/25/2022]
Abstract
PURPOSE To investigate the outcome of mitomycin C (MMC)-augmented trabeculectomy with subconjunctival bevacizumab in the management of Fuchs heterochromic iridocyclitis (FHI)-related glaucoma in 1-year follow-up period. METHODS This retrospective study included 50 eyes with FHI-related glaucoma those had underwent initial trabeculectomy with MMC (0.2 mg/ml-3 min). Thirty-one of them had single-dose bevacizumab injection (1.25 mg/0.05 ml) into the bleb area just at the end of the surgery, while 19 eyes did not have. The intraocular pressure (IOP) and the mean number of anti-glaucomatous medications were evaluated. The IOP value ≤ 21 mmHg was defined as complete or qualified surgical success in terms of using medical anti-glaucomatous treatment. Bleb height and vascularity were evaluated with Indiana bleb grading system. Paired sample t test, t test, Chi-square and Kolmogorov-Smirnov tests were used for statistical analysis. RESULTS The preoperative IOP values of bevacizumab and without bevacizumab groups were 32.8 ± 4.5 mmHg and 32.8 ± 4.5 mmHg, respectively, and they decreased to 17.5 ± 4.6 mmHg and 17 ± 5.2 mmHg at the final visit (p < 0.001 for all values). There were no significant differences in postoperative IOP and the number of medications between the groups at the final visit. In bevacizumab group, complete success was achieved in 100% within the third month but decreased to 22.5% (complete) and 74.1% (qualified) at the first year. In the other group (without bevacizumab group), complete success was achieved in 94.7% within the third month but decreased to 15.8% (complete) and 84.2% (qualified) at the first year. CONCLUSION Initial trabeculectomy with MMC and subconjunctival bevacizumab injection was found to have lower rates of complete success with relatively acceptable qualified success rates in the management of FHI-related glaucoma. Subconjunctival bevacizumab was not found to have additional effect to improve the surgical success.
Collapse
Affiliation(s)
- Ufuk Elgin
- Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey.
| | - Emine Sen
- Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey
| | - Kubra Ozdemir
- Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey
| | - Pinar Ozdal
- Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey
| | - Nilufer Berker
- Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey
| |
Collapse
|
2
|
Abstract
PRECIS Wider area bleb revision using bleb knife with adjunctive mitomycin C (MMC) had a good success rate, according to strict success criteria, except in patients with neovascular glaucoma (NVG). PURPOSE We determined the efficacy of wider area bleb revision after filtering surgery using bleb knife with adjunctive MMC. PATIENTS AND METHODS In this retrospective single-center study, we analyzed 86 patients with glaucoma (46 primary open-angle, 18 exfoliations, 13 secondary, and 9 neovascular) after bleb revision using bleb knife with adjunctive MMC after a minimum follow-up of 6 months. A Kaplan-Meier survival analysis with log-rank tests and Cox proportional hazards regression analyses were performed. The main outcome measure was a successful initial bleb revision using bleb knife with adjunctive MMC, arbitrarily defined as intraocular pressure (IOP) control <15 mm Hg without any IOP-lowering medication, additional bleb revision, or glaucoma surgery. RESULTS The mean time since the initial filtering surgery was 243.8 days, and the mean prebleb revision IOP was 22.0±4.8 mm Hg. The total cumulative success rate of the bleb revision using bleb knife with MMC was 49% at 6 months and 30% at 1 year. Patients with primary open-angle glaucoma had the best success rate (64% at 6 mo and 40% at 1 y). Log-rank tests revealed that patients with NVG had the worst prognosis (P<0.01). NVG was the only significant risk factor identified for short survival time (odds ratio, 167.10; 95% confidence interval, 1.78-15620.44; P=0.027). CONCLUSION Wider area bleb revision using bleb knife with adjunctive MMC had a good success rate, according to strict success criteria, except in patients with NVG.
Collapse
|
3
|
Rabiolo A, Marchese A, Bettin P, Monteduro D, Galasso M, Dolci MP, Di Matteo F, Fiori M, Ciampi C, Bandello F. Needle revision outcomes after glaucoma filtering surgery: survival analysis and predictive factors. Eur J Ophthalmol 2019; 30:350-359. [DOI: 10.1177/1120672119830861] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose: To evaluate the efficacy and safety of needle revision and examine factors predictive of failure. Methods: In total, 157 eyes of 131 patients that underwent needle revision augmented with either 5-fluorouracil or betamethasone for trabeculectomy failure were included in this retrospective study. Complete failure was defined as additional glaucoma surgery, ciliodestructive procedures, loss of light perception, sight-threatening complications, hypotony maculopathy, and surgical bleb revision. Success was defined as intraocular pressure ⩽ 18 (criterion A), ⩽15 (criterion B), and ⩽12 mmHg (criterion C) reached with (qualified) or without (complete) medications, and absence of any criteria of complete failure. Results: The median (interquartile range) follow-up was 25.0 (41.0) months. Complete failure rates were 19%, 26%, and 31% at 1, 2, and 3 years, respectively. For criterion A, qualified and complete success rates were, respectively, 77% and 69% at 1 year, 66% and 51% at 2 years, and 60% and 47% at 3 years. For criterion B, qualified and complete success rates were, respectively, 67% and 61% at 1 year, 48% and 42% at 2 years, and 44% and 39% at 3 years. For criterion C, qualified and complete success rates were, respectively, 43% and 41% at 1 year, 27% and 25% at 2 years, and 24% and 23% at 3 years. High baseline intraocular pressure and primary surgery were associated with higher and lower risks of complete failure, respectively. Conclusion: Needle revision is an effective and safe procedure to rescue failing trabeculectomy postponing or avoiding further glaucoma surgery. Eyes with low target intraocular pressure may have poor long-term outcomes.
Collapse
Affiliation(s)
- Alessandro Rabiolo
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Alessandro Marchese
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Paolo Bettin
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Davide Monteduro
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
- Department of Biomedical and Clinical Science “Luigi Sacco,” Eye Clinic, Sacco Hospital, University of Milan, Milan, Italy
| | - Mario Galasso
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Maria Paola Dolci
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Federico Di Matteo
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Marina Fiori
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Carlo Ciampi
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Francesco Bandello
- Department of Ophthalmology, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy
| |
Collapse
|
4
|
Lanzagorta-Aresti A, Perez-Lopez M, Davo-Cabrera JM, Palacios-Pozo E. Prospective pilot study comparing deep sclerectomy outcomes with a long-term and intense corticosteroid treatment versus a standard one. BMJ Open Ophthalmol 2018; 3:e000165. [PMID: 30519640 PMCID: PMC6243469 DOI: 10.1136/bmjophth-2018-000165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2018] [Revised: 09/13/2018] [Accepted: 09/24/2018] [Indexed: 11/04/2022] Open
Abstract
Objective To compare prospectively intraocular pressure (IOP) results after deep sclerectomy (DS) using a topical short-term corticosteroid treatment (STCT, 1 month) versus a topical long-term and intense corticosteroid treatment (LTCT, 6 months) in a two2 year-follow-up. Methods Patients with medically uncontrolled open angle glaucoma were prospectively recruited and underwent a DS. Results We operated 45 eyes of 45 patients, 22 in STCT group and 23 in LTCT group. Median preoperative IOP was 27 (22-36.75) mm Hg for STCT and for 25 (22-28) mm Hg for LTCT group without significant difference (p=0.195). Median postoperative IOP was 4 (3-6.25) mm Hg in STCT group versus 2 (0-5) mm Hg in LTCT at day 1 (p=0.003); 8.5 (5.75-11.25) mm Hg (STCT) vs 6 (4-9) mm Hg (LTCT) at week 1 (p=0.079); 17.5 (14.75-22.25) mm Hg (STCT) vs 13 (10-14) mm Hg (LTCT) at month 1 (p=0.001); 16 (12-20) mm Hg (STCT) vs 12 (10-15) mm Hg (LTCT) at month 3 (p=0.008); 17 (14-20) mm Hg (STCT) vs 12 (10-14) mm Hg (LTCT) at month 6 (p=0.000); 16 (14-20) mm Hg (STCT) vs 14 (10-16) mm Hg (LTCT) at year 1 (p=0.002) and 17.5 (15-19) mm Hg (STCT) vs 14 (12-16) mm Hg (LTCT) at year 2 (p=0.001). The complete success rate was 54.5 % in STCT and 87 % in LTCT (p=0.018). Conclusions A long-term and intensive postoperative treatment enhances success rate in DS compared with a standard protocol.
Collapse
Affiliation(s)
| | - Marta Perez-Lopez
- Glaucoma and Neuro-Ophthalmology Department, FISABIO Oftalmologia, Valencia, Spain
| | | | - Elena Palacios-Pozo
- Glaucoma and Neuro-Ophthalmology Department, FISABIO Oftalmologia, Valencia, Spain
| |
Collapse
|
5
|
Sii S, Barton K, Pasquale LR, Yamamoto T, King AJ, Azuara-Blanco A. Reporting Harm in Glaucoma Surgical Trials: Systematic Review and a Consensus-Derived New Classification System. Am J Ophthalmol 2018; 194:153-162. [PMID: 30053474 DOI: 10.1016/j.ajo.2018.07.014] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 06/18/2018] [Accepted: 07/15/2018] [Indexed: 11/28/2022]
Abstract
PURPOSE To evaluate the standards of harm reporting for glaucoma surgical trials and to develop a classification system for reporting surgical complication severity. DESIGN Systematic review and Delphi consensus method. METHODS Systematic review of glaucoma surgical trials published from January 2010 until July 2017 with a quality assessment against the CONSORT checklist for harm. A Delphi method was employed to generate consensus grading (interquartile range ≤ 2) among international glaucoma experts (n = 43) on severity of glaucoma surgical complications, and specifically for trabeculectomy and aqueous shunt complications, from 1 (no clinical significance) to 10 (most severe complication). RESULTS Forty-seven studies were eligible. The items of the CONSORT checklist for harm that were most frequently missing were use of a validated instrument to report severity (0%), withdrawals due to harm, and subgroup analyses, both reported in 3 publications (6.4%). Most glaucoma experts participating in the Delphi process (80%) completed the second round, and consensus was achieved for all but 1 complication. The least severe complications (graded 2) were "transient loss of vision," "early low intraocular pressure," "choroidal detachment anterior to equator," "small layered hyphema < 1 mm," and "increased lens opacity not clinically significant." The most severe complications (graded 10) were "endophthalmitis" and "permanent severe loss of vision (hand movements or worse)." CONCLUSIONS Glaucoma surgical randomized controlled trials report frequency of complications, but their severity is rarely reported. The quality of harm reporting is poor. We propose the use of a newly developed system of classification for assessing the severity of surgical complications based on consensus.
Collapse
Affiliation(s)
- Samantha Sii
- Belfast Health and Social Care Trust, Belfast, United Kingdom
| | - Keith Barton
- Glaucoma Service, Moorfields Eye Hospital, London, United Kingdom; University College London Institute of Ophthalmology, London, United Kingdom
| | - Louis R Pasquale
- Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
| | - Tetsuya Yamamoto
- Department of Ophthalmology, Gifu University Graduate School of Medicine, Gifu-shi, Japan
| | - Anthony J King
- Department of Ophthalmology, Nottingham University Hospital, Nottingham, United Kingdom
| | | |
Collapse
|
6
|
Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma. Int Ophthalmol 2018; 39:1211-1217. [DOI: 10.1007/s10792-018-0926-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 04/13/2018] [Indexed: 12/25/2022]
|
7
|
Abstract
Purpose To investigate the safety and synergistic effect of topical bevacizumab after trabeculectomy surgery with mitomycin C (MMC). Methods In this prospective, non-randomized, comparative interventional study, 40 eyes from 40 patients with uncontrolled open-angle glaucoma were studied after they underwent primary trabeculectomy with mitomycin C (0.02% for 2 min). Following the procedure topical bevacizumab (4 mg/mL) was used for 2 weeks 4 times daily in group A. Patients in group B received routine postoperative care. The outcome measures were the intraocular pressure (IOP), number of anti-glaucoma medications, complications, and bleb evaluation. Results Of the 32 eyes that had at least 6 months follow-up, 16 were treated with adjuvant topical bevacizumab. The mean preoperative IOP in group A improved from 26.7 ± 9.3 mmHg with 2.8 ± 1.3 anti-glaucoma medications to 10.5 ± 2.8 mmHg with 0.7 ± 1 anti-glaucoma medications at last follow-up (P < 0.001). The mean preoperative IOP in group B improved from 21.8 ± 6.6 mmHg with 3 ± 0.8 anti-glaucoma medications to 11.4 ± 3.6 mmHg with 0.8 ± 1.2 anti-glaucoma medications at last follow-up (P < 0.001). There was an overall reduction of 54.4% and 43.7% in the IOP in groups A and B, respectively (P = 0.18). The cystic type of bleb was less common in group A (P = 0.043). One patient in group A developed a streptococcal corneal ulcer 1.5 months after surgery. Conclusion Administration of topical bevacizumab 4 mg/ml for two weeks following trabeculectomy with mitomycin-C did not significantly affect the IOP trend, but significantly decreased the cystic bleb formation in short-term follow-up.
Collapse
|
8
|
Liu X, Du L, Li N. The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) 2016; 95:e3223. [PMID: 27082560 PMCID: PMC4839804 DOI: 10.1097/md.0000000000003223] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The aim of the study was to assess the effects of bevacizumab in augmenting trabeculectomy for glaucoma. We searched the databases of Cochrane Library, PubMed, Embase, CNKI, and VIP. All the databases were retrieved from the time databases established to September, 2015. The keywords we used were as follows: "bevacizumab," "anti-VEGF," "avastin," "trabeculectomy," "glaucoma," and so on. We used a method of the freedom word search and the MeSH search combined, which was recommended by Cochrane Systematic Review Manual 5.1.2. Randomized controlled trails (RCTs) of frequently used bevacizumab in trabeculectomy for glaucoma were included. Study selection, data extraction, quality assessment, and data analysis were performed according to the Cochrane standards. Eight randomized controlled trails involving 212 eyes in the experimental (bevacizumab or bevacizumab + mitomycin C) groups and 214 eyes in the control (mitomycin C or placebo) groups were selected. Compared with placebo, bevacizumab significantly increased the complete success rate [OR = 2.79, 95%CI, (1.47, 5.29), P = 0.002], what else, bevacizumab also significantly decreased the intraocular pressure (IOP) [MD = 3.07, 95% CI, (0.87, 5.27), P = 0.006] at the 6-month after trabeculectomy and the number of antiglaucoma medications [MD = 1.23, 95% CI, (0.66, 1.80), P < 0.0001]. Additionally, it also increased the risk of bleb leak [OR = 5.24, 95% CI, (1.30, 21.10), P = 0.02]. When compared with mitomycin C (MMC), bevacizumab significantly increased the rate of encysted blebs [OR = 4.62, 95% CI, (1.02, 20.91), P = 0.05]. However, there was no significantly difference between the bevacizumab + MMC groups and MMC groups whatever the items were. Bevacizumab was an effective way in trabeculectomy concerning the complete success rate, IOP, and anti-glaucoma medications reduction when compared with placebo; however, it increased the risk of bleb leakage. And it significantly increased the rate of encysted blebs compared with MMC.
Collapse
Affiliation(s)
- Xiaoyan Liu
- From the Department of Ophthalmology (XL, NL), West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; and Chinese Evidence-Based Medicine/Cochrane Center (LD), Chengdu, Sichuan Province, China
| | | | | |
Collapse
|
9
|
Abstract
Vascular endothelial growth factor (VEGF) is a signaling protein, that controls vasculogenesis, angiogenesis, vascular support and stimulates permeability of small blood vessels. The following isoforms are presently known: VEGF-A, VEGF-B, VEGF-C, VEGF-В and PGF. VEGF-A, that regulates neoangiogenesis and fibroblast formation, is thought to play the most important role in human organism. Increased expression of VEGF may lead to development and aggravation of pathological conditions including oncology. The article presents a review of preclinical and clinical studies of the main VEGF-inhibitors - bevacizumab and ranibizumab, as well as a brief account on other existing medications of this group. It describes ophthalmological indications for the use of antiangiogenetic agents, as well as the ways of their possible off-label use. The review presents investigations of intravitreal and intracameral injections of VEGF-inhibitors in patients with retinal, chorioidal, iris, and anterior chamber angle neovascularization. It gives examples of successful anti-VEGF use before Ahmed glaucoma valve drainage device implantation and in cases of neovascular glaucoma, induced by radiation therapy for intraocular tumors. Tenon’s capsule’s fibroblasts take part in the process of postoperative wound healing and scarring. According to the latest research, this process could be modulated by angiogenesis inhibitors. This review also recounts the use of anti-angiogenic agents to inhibit postoperative fibroblast proliferation, when used as monotherapy, or as an adjuvant to mitomycin С or 5-fluorouracil. It reviews the research on VEGF-inibitors use in combination with postoperative needling.
Collapse
|
10
|
Wu KY, Lai YH, Yang YC, Wu WC, Hong SJ. 5-Fluorouracil-Induced Apoptosis Changes in Cultured Corneal Epithelial Cells. J Ocul Pharmacol Ther 2016; 32:155-62. [PMID: 26785286 DOI: 10.1089/jop.2015.0109] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
PURPOSE Repeated subconjunctival injections with 5-fluorouracil (5-FU) after trabeculectomy are used in glaucoma patients for the inhibition of overproliferation in wound site. Thus, a certain amount of the drug may penetrate into epithelial layer, where it causes toxicity to corneal epithelial cells. The aim of this study was to evaluate the toxic effects of 5-FU and mechanisms of drug-induced apoptosis in cultured corneal epithelial cells. METHODS Cellular damage and the caspase pathway were estimated with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The apoptotic characteristics were detected by flow cytometry, a TUNEL test, and western blotting in cultured corneal epithelial cells. RESULTS The results indicated that 5-FU was toxic to corneal epithelial cells in a time- and dose-dependent manner. Pretreatment with a general caspase inhibitor (Z-VAD-FMK), a caspase-8 inhibitor (Z-IETD-FMK), and a caspase-9 inhibitor (Z-LEHD-FMK) reversed 5-FU-induced cellular damage. Following exposure to 5-FU, a flow cytometric assay with MitoLight dye demonstrated the significant loss of mitochondrial membrane potential. A positive TUNEL test revealed that cellular DNA apoptosis occurred following exposure to 0.5, 1, and 5 mg/mL 5-FU for 15 h. Positive annexin V-FITC and negative propidium iodide (PI) staining indicated that the cell membrane exhibited apoptosis upon exposure to 1 and 5 mg/mL 5-FU for 15 h. The western blot assay demonstrated upregulation of the p21 protein but downregulation of the Bcl-2 proteins induced by 5-FU. CONCLUSION These data reveal that 5-FU-induced cellular apoptosis in corneal epithelial cells may be mediated through caspase-8, caspase-9, and mitochondria-regulated pathways, as well as by upregulation of p21 and downregulation of Bcl-2-dependent signal transduction pathways.
Collapse
Affiliation(s)
- Kwou-Yeung Wu
- 1 Department of Ophthalmology, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan .,2 Department of Ophthalmology, Kaohsiung Medical University Hospital , Kaohsiung, Taiwan
| | - Yu-Hung Lai
- 1 Department of Ophthalmology, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan .,2 Department of Ophthalmology, Kaohsiung Medical University Hospital , Kaohsiung, Taiwan
| | - Yu-Chiao Yang
- 3 Department of Pharmacology, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan
| | - Wen-Chuan Wu
- 1 Department of Ophthalmology, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan .,2 Department of Ophthalmology, Kaohsiung Medical University Hospital , Kaohsiung, Taiwan
| | - Show-Jen Hong
- 3 Department of Pharmacology, College of Medicine, Kaohsiung Medical University , Kaohsiung, Taiwan
| |
Collapse
|
11
|
Prospective study comparing mitomycin C or bevacizumab as adjuvant in trabeculectomy revision by needling. Eur J Ophthalmol 2015; 26:221-5. [PMID: 26449256 DOI: 10.5301/ejo.5000688] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2015] [Indexed: 11/20/2022]
Abstract
PURPOSE To compare the use of mitomycin C (MMC) or bevacizumab (BEV) as adjunctive in the needling revision of failed trabeculectomy blebs. METHODS Glaucoma patients with failed trabeculectomy were included. Cystic blebs were excluded. All procedures were performed by the same surgeon at the operating room under peribulbar blockade. Rate of success, intraocular pressure (IOP), and number of antiglaucoma drugs in use were compared before and after the procedures. The IOP was measured postoperatively at days 1, 30, 90, and 180. Absolute success was defined as IOP ≤18 mm Hg, without any complication or use of any antiglaucomatous drugs. Qualified success was the same criteria, but with the use of any antiglaucomatous drugs. RESULTS Twenty-nine eyes of 29 patients were included: 15 eyes with MMC and 14 eyes with BEV. There was no statistical difference in the IOP reduction between the groups (MMC 32.6 ± 16.1% vs BEV 30.1 ± 12.0%, p = 0.6). The BEV group showed similar reduction in the number of antiglaucoma drugs compared to the MMC group (p = 0.6). Absolute success was found in 28.5% of the BEV group and in 6.6% of patients with MMC. Qualified success was found in 64.3% and 73.4%, respectively, both limited to 180 days. CONCLUSIONS In this selected and limited group of patients, bevacizumab can be considered as an alternative to MMC in the needling revision of failed trabeculectomy. Studies with a larger number of patients and longer follow-up are needed to confirm the hypothesis suggested here.
Collapse
|
12
|
Fan Gaskin JC, Nguyen DQ, Soon Ang G, O'Connor J, Crowston JG. Wound Healing Modulation in Glaucoma Filtration Surgery- Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II). J Curr Glaucoma Pract 2014; 8:46-53. [PMID: 26997808 PMCID: PMC4741169 DOI: 10.5005/jp-journals-10008-1160] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Accepted: 12/02/2013] [Indexed: 12/16/2022] Open
Abstract
Glaucoma filtration surgery is regularly performed for the treatment of glaucoma and trabeculectomy is often regarded as the ‘gold standard' glaucoma operation. The biggest risk of failure of the operation is bleb scarring. The advent of antifibrotic agents, such as mitomycin C (MMC) and 5-fluorouracil (5FU) has vastly prolonged the longevity of the bleb, but concerns remain regarding the potential increase in postoperative complications. More selective therapeutic targets have therefore been explored. One of these is vascular endothelial growth factor (VEGF) inhibition. VEGF inhibition has a role not only in subconjunctival angiogenesis inhibition but also it has direct anti-fibrotic properties. Newer pharmacological compounds and materials have also been developed in recent years in attempt to modulate the wound healing in different ways after glaucoma surgery. These include physical barriers to scarring and vehicles for sustained release of pharmacological agents, and early promising results have been demonstrated. This two-part review will provide a discussion of the application of anti-fibrotic agents in glaucoma filtration surgery and evaluate the newer agents that have been developed. How to cite this article: Fan Gaskin JC, Nguyen DQ, Ang GS, O'Connor J, Crowston JG. Wound Healing Modulation in Glau coma Filtration Surgery–Conventional Practices and New Pers pectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II). J Curr Glaucoma Pract 2014;8(2):46-53.
Collapse
Affiliation(s)
- Jennifer C Fan Gaskin
- Glaucoma Fellow, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia
| | - Dan Q Nguyen
- Consultant, Department of Ophthalmology, Mid Cheshire Hospitals, NHS Foundation Trust, Cheshire; Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, UK
| | - Ghee Soon Ang
- Consultant, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia
| | - Jeremy O'Connor
- Consultant, Glaucoma Investigation and Research Unit, University Hospital Limerick, Ireland
| | - Jonathan G Crowston
- Professor, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia
| |
Collapse
|
13
|
Xiong Q, Li Z, Li Z, Zhu Y, Abdulhalim S, Wang P, Cai X. Anti-VEGF agents with or without antimetabolites in trabeculectomy for glaucoma: a meta-analysis. PLoS One 2014; 9:e88403. [PMID: 24523890 PMCID: PMC3921170 DOI: 10.1371/journal.pone.0088403] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2013] [Accepted: 01/05/2014] [Indexed: 12/11/2022] Open
Abstract
PURPOSE We aimed to evaluate the intraoperative application of antimetabolites compared with anti-vascular endothelial growth factor (VEGF) agents with or without antimetabolites in trabeculectomy (Trab) for glaucoma. METHODS Relevant studies were selected through extensive search using PubMed, EMBASE, the Cochrane Library, and Web of Science databases in August 2013. The primary efficacy estimate was measured using weighted mean difference of the percentage of intraocular pressure reduction (IOPR%) from baseline to end-point, and the secondary efficacy estimates were odds ratio (OR) and 95% confidence interval (CI) for complete success rate and qualified success rate. ORs were also used to measure the tolerability estimate for adverse events. Meta-analyses of fixed or random effects models were conducted using RevMan software 5.2 to pool the results of the studies included. Heterogeneity was assessed using Chi(2) test and the I(2) measure. RESULTS Nine studies enrolling a total of 349 patients were included. The weighted mean difference of IOPR% from baseline was 7.23 (95% CI: 2.57-11.89) for antimetabolites vs. anti-VEGF agents and 3.96 (95% CI: -4.18-12.10) for antimetabolites vs. anti-VEGF agents plus antimetabolites. The pooled ORs comparing antimetabolites with anti-VEGF agents were 2.37 (95% CI: 0.78, 7.21) for the complete success rate and 1.93 (95% CI: 0.52, 7.16) for qualified success rate. The pooled ORs comparing antimetabolites with anti-VEGF agents plus antimetabolites were 1.43 (95% CI: 0.48, 4.29) for the complete success rate and 2.11 (95% CI: 0.12, 37.72) for qualified success rate. The rates of adverse events did not significantly differ between antimetabolites and anti-VEGF agents, with pooled ORs of 0.86 (0.28-2.69) for bleb leakage, 3.01 (0.45-20.10) for choroidal effusion, 0.96 (0.23-3.98) for flat anterior chamber, and 0.90 (0.12-6.60) for hypotony. Further, the rates of adverse events were similar between antimetabolites and anti-VEGF agents plus antimetabolites, with pooled ORs of 0.40 (0.08-2.00) and 8.00 (0.93-68.59) for bleb leakage and hypotony, respectively. CONCLUSIONS In comparison with anti-VEGF agents, antimetabolites were more effective in lowering IOP in Trab, while the intraoperative application of these two types of agents did not indicate statistically significant differences in the complete success rate, qualified success rate, or incidence of adverse events.
Collapse
Affiliation(s)
- Qi Xiong
- Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
| | - Zhiliang Li
- Department of Orthpedics, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China
| | - Zhaohui Li
- Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
| | - Yi Zhu
- Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
| | - Sancar Abdulhalim
- Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
| | - Ping Wang
- Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
| | - Xiaojun Cai
- Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
- * E-mail:
| |
Collapse
|
14
|
Hong SJ, Wu WC, Lai YH, Wu KY. Mechanism of 5-Fluorouracil-Induced Apoptosis on Cultured Corneal Endothelial Cells. ACTA ACUST UNITED AC 2014. [DOI: 10.4236/ojapo.2014.32002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
15
|
Abstract
Preoperative treatment with steroids and nonsteroidal anti-inflammatory drugs increases the success of filtration surgery. Surgery with the patient under subconjunctival anesthesia is safe. Intraoperative application of mitomycin C is state of the art and enhances success rates. Perioperative use of bevacizumab seems to attenuate postoperative fibrosis. Postoperative hypotension is avoided by stable fixation of the scleral flap followed by stepwise controlled suturelysis or release. Transconjunctival flap suturing allows fast and simple treatment of overfiltration. The shorter the time lag between trabeculectomy and subsequent cataract surgery the higher the probability of bleb failure will be. The number of antiglaucomatous drugs and severity of glaucomatous damage before surgery correlate with the probability of failure and blindness.
Collapse
Affiliation(s)
- T Klink
- Universitäts-Augenklinik Würzburg, Josef-Schneider-Str. 11, 97080 Würzburg.
| | | |
Collapse
|